Trial Profile

Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (the NIPU-study)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; UV 1 (Primary) ; UV 1 (Primary)
Indications Malignant-mesothelioma
Focus Proof of concept; Therapeutic Use
Acronyms CA209-7HF NIPU; NIPU

21 Aug 2024 According to an Ultimovacs AS media release, patients from Australia, Spain and Scandinavia were enrolled in the study between June 2020 and January 2023. Denmark, Norway and Sweden were planned locations.
01 Aug 2024 According to an Ultimovacs AS media release, data from this study will be presented in a poster presentation at the 2024 ESMO Congress. The conference will be held in Barcelona, Spain from September 13-17, 2024.
07 May 2024 According to an Ultimovacs AS media release, mature overall survival data from the NIPU trial is expected to be reported later in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com